Below is a list with tagged columns and company profiles.

Today's Headlines Healthcare

  • 70% of the Indonesian Population Joins Universal Healthcare Program

    70% of the Indonesian Population Joins Universal Healthcare Program

    Per September 2017 around 70 percent of the Indonesian population participates in the government's universal healthcare program (in Indonesian: Jaminan Kesehatan Nasional or JKN), a program that was implemented by the social security agency Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS) in early 2014. This government-subsidized program aims to provide all Indonesian citizens with access to a wide range of health services by 2019.

    Read more ›

  • Shares of Mitra Keluarga Karyasehat Plunge after Death Baby

    Shares of Mitra Keluarga Karyasehat Plunge after Death Baby

    During the first trading session on Monday (11/09) shares of Mitra Keluarga Karyasehat, Indonesia's largest listed hospital operator in terms of market capitalization, plunged 4.27 percent to IDR 2,020 per share after a high degree of negative attention in Indonesian media. This weak performance is linked to a scandal that emerged over the weekend.

    Read more ›

  • Hospital Industry Indonesia Attractive, Plenty of Growth Potential

    Hospital Industry Indonesia Attractive, Plenty of Growth Potential

    The hospital sector of Indonesia is promising. Therefore, several investors are eager to expand into the nation's hospital business. For example, the Mayapada Group will add five hospitals to its portfolio over the next 12 months. Another example is Mitra Keluarga Karyasehat that also plans to acquire a number of hospitals with a focus on the new market that is created under the central government's universal healthcare program.

    Read more ›

  • Siloam International Hospitals Ready for Rights Issue

    Siloam International Hospitals Ready for Rights Issue

    Siloam International Hospitals, Indonesia's largest private hospital operator, received the green light from shareholders to conduct a rights issue. Through the rights issue the company will issue 325.2 million brand new shares, equivalent to 25 percent of its enlarged share capital. Siloam aims to obtain IDR 3.09 trillion (approx. USD $232 million) worth of fresh funds through the corporate move.

    Read more ›

  • Pharmaceutical Industry Indonesia: Is 10% Growth Possible in 2017?

    Pharmaceutical Industry Indonesia: Is 10% Growth Possible in 2017?

    Indonesia's pharmaceutical industry remains promising for foreign investors, evidenced by rising growth in the first half of the year. For the first time in three years growth in Indonesia's pharmaceutical industry could touch double-digit figures again. Parulian Simanjuntak, Executive Director of the International Pharmaceutical Manufacturers Group (IPMG), said the industry has improved compared to the situation one year ago.

    Read more ›

  • Foreign Investment in Indonesia's Pharmaceutical Industry

    Foreign Investment in Indonesia's Pharmaceutical Industry

    Foreign pharmaceutical companies have already invested more than USD $1 billion in Indonesia over the past couple of years. These investments involves 34 companies that are all members of the International Pharmaceutical Manufacturers Group (IPMG). Parulian Simanjuntak, IPMG Executive Director, informed that these investments have been conducted not only to establish new factories but also for other forms of business expansion as well as marketing. It is estimated that 205 pharmaceutical companies are competing for market share in Indonesia.

    Read more ›

  • Developing a Self-Sufficient Pharmaceutical Industry in Indonesia

    Developing a Self-Sufficient Pharmaceutical Industry in Indonesia

    Indonesian President Joko Widodo signed Presidential Instruction No. 6/2016 on the Acceleration of Development of the Pharmaceutical Industry and Medical Devices on 8 June 2016. Through this instruction Widodo calls on all relevant ministries - including the Health Ministry, Industry Ministry and Finance Ministry - to take efforts to boost development of Indonesia's pharmaceutical industry. The Health Industry has a key task to write an action plan for the development of a self-sufficient pharmaceutical industry and to boost competitiveness.

    Read more ›

  • Indonesia's Watsons Operator Duta Intidaya Made Trading Debut

    Indonesia's Watsons Operator Duta Intidaya Made Trading Debut

    On Tuesday (28/06) Duta Intidaya became the 7th company to list on the Indonesia Stock Exchange (IDX) in 2016. The company, an Indonesia-based health & beauty products retailer and specifically known for being the operator of the Watsons stores in Indonesia, made a solid trading debut. Its shares rose five percent to finish at IDR 189 per piece. Through the initial public offering (IPO), Duta Intidaya seeks new funds for business expansion and debt settlement. The company is set to open new branches and expand its e-commerce activities.

    Read more ›

  • 11th Stimulus Package: Pharmaceutical Industry of Indonesia

    11th Stimulus Package: Pharmaceutical Industry of Indonesia

    For its raw materials the pharmaceutical industry of Indonesia is highly dependent on imports. Around 90 percent of medicines' raw materials, roughly IDR 7 trillion (approx. USD $526 million), may be imported this year. Meanwhile, given the Indonesian government is eager to develop its universal health care program (launched in 2014), demand for pharmaceutical products in Indonesia is expected to rise further. Total clients under the national health insurance program is expected to rise from 162 million in 2015 to 186 million in 2016. By the year 2019 the government wants to provide universal health care to all Indonesians.

    Read more ›

  • Indonesia's National Health Insurance Program: Rising Financial Mismatch

    Indonesia's National Health Insurance Program: Rising Financial Mismatch

    There is a growing mismatch between claims paid and premiums received by Indonesia's Healthcare and Social Security Agency (Badan Penyelenggara Jaminan Sosial, or BPJS Kesehatan). This year the deficit could reach IDR 9.8 trillion (approx. USD $731 million), leading to concern about the financial sustainability of the program and the need to search for additional and innovative ways to fund Indonesia's National Health Insurance (Jaminan Kesehatan Nasional, or JKN) program.

    Read more ›

Latest Columns Healthcare

  • Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Developing Upstream Facilities in Indonesia's Pharmaceutical Industry

    Vincent Harijanto, Head of the Indonesian Pharmaceutical Association (GP Farmasi) business development committee, said about 95 percent of raw materials used in Indonesia's pharmaceutical industry need to be imported from abroad. This dependence on imports causes several problems, for example prices of pharmaceutical products are relatively high on the Indonesian market, while Indonesian pharmaceutical companies (and Indonesian consumers) can suddenly face rising prices in times of rupiah depreciation.

    Read more ›

  • Difficult for Indonesia to Become an Innovation-Driven Economy

    Difficult for Indonesia to Become an Innovation-Driven Economy

    A new report shows Indonesia lacks behind its regional peers in terms of innovation. This is a concern because it means Indonesia's workforce is not equipped with the skills, knowledge or health that are necessary to be innovation-driven. Therefore, the Indonesian government needs to remain focused on enhancing the quality of education and healthcare. Innovation is widely regarded as a driver of economic growth and development.

    Read more ›

  • Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Pharmaceutical Exports Indonesia Remain Under Pressure in 2017

    Exports of pharmaceutical products from Indonesia have declined due to increasing competition from China on the international market. Chinese pharmaceutical companies dominate export markets supported by China's low production cost environment and the availability of raw materials at home. However, despite this situation, the Indonesian Pharmacy Association (GP Farmasi Indonesia) remains optimistic that Indonesia's pharmaceutical exports can climb in 2017.

    Read more ›

  • Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    Indonesian Pharmaceutical Companies in Focus: Kimia Farma

    State-controlled pharmaceutical company Kimia Farma is expected to show steadily improving corporate earnings in the years ahead supported by Indonesia's universal healthcare scheme (in Indonesian: Jaminan Kesehatan Nasional or JKN) that was implemented by the social security agency Badan Penyelenggara Jaminan Sosial Kesehatan (BPJS) in early 2014. The scheme aims to provide all Indonesian citizens with access to a wide range of health services. Obviously, local pharmaceutical companies are in a great position to benefit from this program.

    Read more ›

  • Hospital Sector Indonesia: Opportunities and Challenges

    Hospital Sector Indonesia: Opportunities and Challenges

    Although Indonesia's National Health Insurance program is not without problems, it does benefit Indonesian hospitals and makes investment in the nation's hospital sector attractive, particularly as the Indonesian government targets to provide universal health care to all Indonesians by the year 2019. Reportedly, those hospitals that receive patients that fall under Indonesia's Healthcare and Social Security Agency (Badan Penyelenggara Jaminan Sosial, or BPJS Kesehatan) are the busiest hospitals in Indonesia at the moment.

    Read more ›

  • Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Pharmaceutical Industry Indonesia: Plagued by Weak Rupiah

    Companies active in the pharmaceutical industry of Indonesia need to find strategies to overcome sharp rupiah depreciation. Indonesia’s pharmaceutical industry is still - to a large extent - dependent on the import of raw materials, hence a weakening rupiah raises the costs of imports thus eroding profit margins. Since May 2013, when the US Federal Reserve started to hint at monetary tightening, the US dollar has experienced bullish momentum. Between the May 2013 and July 2015, the rupiah depreciated around 37 percent against the US dollar.

    Read more ›

  • Malnutrition in Indonesia: 8.4 Million Children Stunted!

    Malnutrition in Indonesia: 8.4 Million Children Stunted!

    A new World Bank report, entitled “The Double Burden of Malnutrition in Indonesia”, says that 37.2 percent of Indonesian children under the age of five - or 8.4 million children - are stunted (meaning excessively small for their age) and suffer from chronic malnutrition. As such, Indonesia has the fifth-highest level of stunting in the world. The report also states that 19.6 percent of Indonesian children under five years old (approximately 4.4 million) are underweight as a result of malnutrition. Public awareness about this issue is low in Indonesia.

    Read more ›

  • IPO News Indonesia Stock Exchange: Mitra Keluarga Karyasehat

    IPO News Indonesia Stock Exchange: Mitra Keluarga Karyasehat

    Mitra Keluarga Karyasehat, a leading Indonesian hospital operator and subsidiary of the Kalbe Group, plans to raise about IDR 4.2 trillion (USD $328 million) in an initial public offering (IPO) on the Indonesia Stock Exchange (IDX) in March 2015. The company plans to offer up to 261.9 million shares, or 18 percent of its enlarged equity, to the public. Five percent of this total constitute new shares, while 13 percent are shares divested by private equity firm Lion Investment Partners.

    Read more ›

  • World Bank Report: How Can Indonesia Avoid the Middle Income Trap?

    World Bank Report: How Can Indonesia Avoid the Middle Income Trap

    On Monday (23/06), the World Bank released its latest analysis regarding the Indonesian economy. In its report, titled ‘Indonesia: Avoiding the Trap’, the World Bank states that Indonesia needs to implement a six reforms in priority areas in order to avoid the so-called middle income trap (referring to the situation where a country gets stuck at a certain income level). Without these critical reforms, the country’s economic growth will slow and may not be able to escape the middle income trap.

    Read more ›